RIZZO, ALESSANDRO
RIZZO, ALESSANDRO
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma
2025 Santoni, Matteo; Mollica, Veronica; Rizzo, Alessandro; Massari, Francesco
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
2024 Brandi G.; Relli V.; Deserti M.; Palloni A.; Indio V.; Astolfi A.; Serravalle S.; Mattiaccio A.; Vasuri F.; Malvi D.; Deiana C.; Pantaleo M.A.; Cescon M.; Rizzo A.; Katoh M.; Tavolari S.
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
2023 Carloni, R.; Sabbioni, S.; Rizzo, A.; Ricci, A. D.; Palloni, A.; Petrarota, C.; Cusmai, A.; Tavolari, S.; Gadaleta-Caldarola, G.; Brandi, G.
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
2023 Rizzo, Alessandro; Carloni, Riccardo; Ricci, Angela Dalia; Cusmai, Antonio; Laforgia, Mariarita; Calabrò, Concetta; Ungaro, Valentina; Oreste, Donato; Sollitto, Mario; Palmiotti, Gennaro; Brandi, Giovanni
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents
2022 Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; Santoni M.; Massari F.
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F.
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma
2022 Carloni, Riccardo; Rizzo, Alessandro; Cusmai, Antonio; Palloni, Andrea; Federico, Alessandro Di; Marco, Mariacristina Di; Massafra, Raffaella; Fanizzi, Annarita; Palmiotti, Gennaro; Brandi, Giovanni
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis
2022 Santoni M.; Massari F.; Rizzo A.; Mollica V.; Cimadamore A.; Montironi R.; Battelli N.
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis
2022 Rizzo A.; Mollica V.; Santoni M.; Massari F.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F.
Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma
2022 Rizzo A.; Mollica V.; Massari F.
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
2022 Santoni, M.; Massari, F.; Bracarda, S.; Grande, E.; Matrana, M. R.; Rizzo, M.; De Giorgi, U.; Basso, U.; Aurilio, G.; Incorvaia, L.; Martignetti, A.; Molina-Cerrillo, J.; Mollica, V.; Rizzo, A.; Battelli, N.
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer
2022 Rizzo A.; Mollica V.; Santoni M.; Massari F.
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis
2022 Rizzo A.; Mollica V.; Santoni M.; Massari F.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
2022 Viscardi G.; Tralongo A.C.; Massari F.; Lambertini M.; Mollica V.; Rizzo A.; Comito F.; Di Liello R.; Alfieri S.; Imbimbo M.; Della Corte C.M.; Morgillo F.; Simeon V.; Lo Russo G.; Proto C.; Prelaj A.; De Toma A.; Galli G.; Signorelli D.; Ciardiello F.; Remon J.; Chaput N.; Besse B.; de Braud F.; Garassino M.C.; Torri V.; Cinquini M.; Ferrara R.
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma
2022 Mollica, V.; Santoni, M.; Matrana, M. R.; Basso, U.; De Giorgi, U.; Rizzo, A.; Maruzzo, M.; Marchetti, A.; Rosellini, M.; Bleve, S.; Maslov, D.; Tawagi, K.; Philon, E.; Blake, Z.; Massari, F.
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis
2022 Rizzo A.; Mollica V.; Massari F.
Genomics and Immunomics in the Treatment of Urothelial Carcinoma
2022 Mollica V.; Massari F.; Rizzo A.; Ferrara R.; Menta A.K.; Adashek J.J.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma | Santoni, Matteo; Mollica, Veronica; Rizzo, Alessandro; Massari, Francesco | 2025-01-01 | CANCER TREATMENT REVIEWS | - | 1.01 Articolo in rivista | 1001306.pdf |
| Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies | Brandi G.; Relli V.; Deserti M.; Palloni A.; Indio V.; Astolfi A.; Serravalle S.; Mattiaccio A.; ...Vasuri F.; Malvi D.; Deiana C.; Pantaleo M.A.; Cescon M.; Rizzo A.; Katoh M.; Tavolari S. | 2024-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | Brandi_2024.pdf; 41598_2024_52991_MOESM8_ESM.zip |
| Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma | Carloni, R.; Sabbioni, S.; Rizzo, A.; Ricci, A. D.; Palloni, A.; Petrarota, C.; Cusmai, A.; Tavol...ari, S.; Gadaleta-Caldarola, G.; Brandi, G. | 2023-01-01 | JOURNAL OF HEPATOCELLULAR CARCINOMA | - | 1.01 Articolo in rivista | - |
| Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis | Rizzo, Alessandro; Carloni, Riccardo; Ricci, Angela Dalia; Cusmai, Antonio; Laforgia, Mariarita; ...Calabrò, Concetta; Ungaro, Valentina; Oreste, Donato; Sollitto, Mario; Palmiotti, Gennaro; Brandi, Giovanni | 2023-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents | Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; S...antoni M.; Massari F. | 2022-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study | Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; My...int Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | Cancers 2022 [MOUSEION04].pdf; cancers-14-04142-s001.zip |
| Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma | Carloni, Riccardo; Rizzo, Alessandro; Cusmai, Antonio; Palloni, Andrea; Federico, Alessandro Di; ...Marco, Mariacristina Di; Massafra, Raffaella; Fanizzi, Annarita; Palmiotti, Gennaro; Brandi, Giovanni | 2022-01-01 | FUTURE MEDICINAL CHEMISTRY | - | 1.01 Articolo in rivista | - |
| Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis | Santoni M.; Massari F.; Rizzo A.; Mollica V.; Cimadamore A.; Montironi R.; Battelli N. | 2022-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |
| Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: A meta-analysis | Rizzo A.; Mollica V.; Santoni M.; Massari F. | 2022-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials | Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G. | 2022-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw | Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.;... Massari F. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Bone agents PCa].pdf |
| Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma | Rizzo A.; Mollica V.; Massari F. | 2022-01-01 | JAMA ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors | Santoni, M.; Massari, F.; Bracarda, S.; Grande, E.; Matrana, M. R.; Rizzo, M.; De Giorgi, U.; Bas...so, U.; Aurilio, G.; Incorvaia, L.; Martignetti, A.; Molina-Cerrillo, J.; Mollica, V.; Rizzo, A.; Battelli, N. | 2022-01-01 | EUROPEAN UROLOGY FOCUS | - | 1.01 Articolo in rivista | Revised Manuscript.pdf |
| Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer | Rizzo A.; Mollica V.; Santoni M.; Massari F. | 2022-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | Journal Clinical Medicne 2022 [Editorial AR].pdf |
| Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis | Rizzo A.; Mollica V.; Santoni M.; Massari F. | 2022-01-01 | CLINICAL GENITOURINARY CANCER | - | 1.01 Articolo in rivista | - |
| Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis | Viscardi G.; Tralongo A.C.; Massari F.; Lambertini M.; Mollica V.; Rizzo A.; Comito F.; Di Liello... R.; Alfieri S.; Imbimbo M.; Della Corte C.M.; Morgillo F.; Simeon V.; Lo Russo G.; Proto C.; Prelaj A.; De Toma A.; Galli G.; Signorelli D.; Ciardiello F.; Remon J.; Chaput N.; Besse B.; de Braud F.; Garassino M.C.; Torri V.; Cinquini M.; Ferrara R. | 2022-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma | Mollica, V.; Santoni, M.; Matrana, M. R.; Basso, U.; De Giorgi, U.; Rizzo, A.; Maruzzo, M.; March...etti, A.; Rosellini, M.; Bleve, S.; Maslov, D.; Tawagi, K.; Philon, E.; Blake, Z.; Massari, F. | 2022-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? | Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, An...drea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis | Rizzo A.; Mollica V.; Massari F. | 2022-01-01 | EUROPEAN UROLOGY FOCUS | - | 1.01 Articolo in rivista | - |
| Genomics and Immunomics in the Treatment of Urothelial Carcinoma | Mollica V.; Massari F.; Rizzo A.; Ferrara R.; Menta A.K.; Adashek J.J. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Gen Immuno UC].pdf |